Linezolid vs Vancomycin in Induced Thrombocytopenia

Area of Science:

• Infectious Diseases
• Pharmacology
• Hematology

Background:

• Linezolid and vancomycin are key treatments for multidrug-resistant gram-positive infections.
• Thrombocytopenia is a known adverse effect of both drugs, potentially leading to treatment discontinuation.
• This study aimed to compare the incidence of thrombocytopenia between linezolid and vancomycin and identify associated risk factors.

Purpose of the Study:

• To compare the incidence of thrombocytopenia in patients treated with linezolid versus vancomycin.
• To identify risk factors contributing to thrombocytopenia in patients receiving these antibiotics.

Main Methods:

• Retrospective observational cohort study.
• Inclusion of patients receiving intravenous or oral linezolid, or intravenous vancomycin for at least 5 days.
• Collection and analysis of platelet count data during treatment to determine thrombocytopenia incidence.

Main Results:

• A total of 453 patients were analyzed (241 linezolid, 212 vancomycin).
• Linezolid use was associated with a significantly higher incidence of thrombocytopenia (OR 4.39; 95% CI 2.38-8.08) compared to vancomycin.
• Advanced age, lower baseline platelet count, and vasopressor use were identified as risk factors for thrombocytopenia.

Conclusions:

• Linezolid carries a substantially higher risk of thrombocytopenia compared to vancomycin.
• Clinicians must consider the elevated risk of thrombocytopenia with linezolid when selecting antibiotic therapy.
• Risk stratification based on age, baseline platelet count, and vasopressor use may aid in patient management.